GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BBS-Bioactive Bone Substitutes PLC (OHEL:BONEH) » Definitions » Equity-to-Asset

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Equity-to-Asset : 0.48 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BBS-Bioactive Bone Substitutes Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BBS-Bioactive Bone Substitutes's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €5.11 Mil. BBS-Bioactive Bone Substitutes's Total Assets for the quarter that ended in Dec. 2023 was €10.61 Mil.

The historical rank and industry rank for BBS-Bioactive Bone Substitutes's Equity-to-Asset or its related term are showing as below:

OHEL:BONEH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06   Med: 0.36   Max: 0.48
Current: 0.48

During the past 9 years, the highest Equity to Asset Ratio of BBS-Bioactive Bone Substitutes was 0.48. The lowest was 0.06. And the median was 0.36.

OHEL:BONEH's Equity-to-Asset is ranked worse than
69.95% of 872 companies
in the Medical Devices & Instruments industry
Industry Median: 0.64 vs OHEL:BONEH: 0.48

BBS-Bioactive Bone Substitutes Equity-to-Asset Historical Data

The historical data trend for BBS-Bioactive Bone Substitutes's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BBS-Bioactive Bone Substitutes Equity-to-Asset Chart

BBS-Bioactive Bone Substitutes Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.31 0.48 0.35 0.40 0.48

BBS-Bioactive Bone Substitutes Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.43 0.40 0.41 0.48

Competitive Comparison of BBS-Bioactive Bone Substitutes's Equity-to-Asset

For the Medical Devices subindustry, BBS-Bioactive Bone Substitutes's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BBS-Bioactive Bone Substitutes's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BBS-Bioactive Bone Substitutes's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where BBS-Bioactive Bone Substitutes's Equity-to-Asset falls into.



BBS-Bioactive Bone Substitutes Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

BBS-Bioactive Bone Substitutes's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=5.108/10.613
=

BBS-Bioactive Bone Substitutes's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=5.108/10.613
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BBS-Bioactive Bone Substitutes  (OHEL:BONEH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


BBS-Bioactive Bone Substitutes Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of BBS-Bioactive Bone Substitutes's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BBS-Bioactive Bone Substitutes (OHEL:BONEH) Business Description

Traded in Other Exchanges
N/A
Address
Kiviharjunlenkki 6, Oulu, FIN, 90220
BBS-Bioactive Bone Substitutes PLC is a health technology company, that develops, designs, and manufactures bioactive bone-graft substitute implants. Its ortho-biological product ARTEBONE, which is based on tricalcium phosphate and a natural spectrum of bone proteins has the capability of bone regeneration.

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Headlines

No Headlines